^
    Back
    Association details:
    Biomarker:RUNX1 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:decitabine (DNMT inhibitor) +
    clofarabine (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Am J Hematol
    Title:

    Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia

    Published date:
    03/26/2021
    Excerpt:
    High response rates and OS were observed in patients with mutations in NPM1, FLT3, IDH2, and RUNX1….The backbone of clofarabine or cladribine and LDAC alternating with decitabine was effective and safe for the treatment of older patients with newly diagnosed AML.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1002/ajh.26206